HIV Vaccine Designed for HIV Infected Adults Taking Anti-HIV Drugs

Completed · Phase 1

Conditions studied: HIV Infections

In brief

This study will evaluate the safety of and immune responses to a dendritic cell vaccination for HIV-1 infection. The vaccine will be made from a patient's own cells combined with small fragments of HIV-1 (made synthetically in a laboratory). These cells will be administered back to the patient either into a vein (intravenously) or the skin (subcutaneously).

Key facts

Study ID

NCT00056758

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

18

Starts

2003-02-01

Last updated by the study team

2007-08-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV-1 infection
• Current CD4 count more than 400/mm3
• HIV RNA less than 400 copies/ml
• Stable combination antiretroviral therapy for at least 4 weeks prior to study entry
• HLA A2.1 (to be tested at screening)

You may not qualify if…

• Prior HIV vaccine
• Systemic steroids or immunosuppressive drugs within 30 days of study entry
• Pregnant or breastfeeding

Where it is running

• University of Pittsburgh, Pitt Treatment Evaluation Unit — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.